Investor Relations
TOP IR CONTENTS
The Latest Presentation Materials
Past Presentation MaterialsConference on FY2025.12 Q2 Financial Results
FY2025 Q2 Overview
Dr. Osamu Okuda,
President & CEO
Overview of Development Pipeline
Tsukasa Kusano,
Executive Vice President, Head of Project & Lifecycle Management Unit
FY2025 Q2 Consolidated Financial Overview (Core)
Iwaaki Taniguchi,
Director, Executive Vice President & CFO
Upcoming Events(Upcoming Events (2 Most Recent))
Events & PresentationsAnnual Report 2024(Integrated Report)
Past Annual Report
What's New
-
Chugai’s PiaSky Launched as Taiwan’s First Approved Subcutaneous Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
Roche’s Announcement Regarding giredestrant (Presentation of Phase III evERA Study Results)
-
Chugai Files for Additional Indication of Avastin for the Treatment of Neurofibromatosis Type 2
-
Chugai Obtains Regulatory Approval for Tecentriq for the Additional Indication of Extranodal Natural Killer/T-cell Lymphoma, Nasal Type, a Rare Disease
-
Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron
External Evaluations
External Evaluations-
ESG Indices of Global Equities
DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA). Companies are selected as a constituent annually based on an assessment of their economic, environmental and social sustainability.
-
ESG Indices Selected by GPIF
Chugai has been continuously included as a constituent stock of the all six ESG indices for Japanese equities since the initiation of ESG investment by the Government Pension Investment Fund (GPIF).
-
IR Activities
Chugai was ranked first for the first time in 2024 in the pharmaceutical sector for the “Selection of Excellent Companies in Corporate Disclosure by Securities Analysts” conducted by the Securities Analysts Association of Japan (SAAJ), a public interest incorporated association.
About Chugai
-
Company Outline
Company Profile, Business Process, Directors & Officers, Organization.
-
History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
R&D
Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
